Respiratory syncytial virus and other respiratory viruses in the setting of bone marrow transplantation

Current Opinion in Oncology

Volumn 21, Issue 2, 2009, Pages 171-176

  Ison, Michael G ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Transplant and Immunocompromised Host ID Service   (United States)

Author keywords

Human metapneumovirus; Infection; Influenza; Respiratory syncytial virus; Respiratory virus; Stem cell transplant

Indexed keywords

ALN RSV 01; ANTIVIRUS AGENT; BENZODIAZEPINE DERIVATIVE; BTA 9881; DAS 181; HEMAGGLUTININ INHIBITOR; IMMUNOGLOBULIN; MOTAVIZUMAB; OSELTAMIVIR; PALIVIZUMAB; PERAMIVIR; PROTEIN INHIBITOR; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RIBAVIRIN; RS 637; RSV 604; SIALIDASE INHIBITOR; T 705; TMC 353121; UNCLASSIFIED DRUG; ZANAMIVIR;

BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN METAPNEUMOVIRUS; INFLUENZA VIRUS; PARAINFLUENZA VIRUS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY VIRUS; REVIEW; VIRAL RESPIRATORY TRACT INFECTION;

ANTIVIRAL AGENTS; BONE MARROW TRANSPLANTATION; HUMANS; PNEUMOVIRUS INFECTIONS; POSTOPERATIVE COMPLICATIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RESPIROVIRUS;

EID: 62349142326     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328324bc1c     Document Type: Review

References (72)

1. Boeckh M. The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br J Haematol 2008; 143:455-467. An outstanding review of RVIs complicating HSCT.
2. Ison MG. Respiratory viral infections in transplant recipients. Antivir Ther 2007; 12:627-638.
3. Peck AJ, Englund JA, Kuypers J, et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood 2007; 110:1681-1688. Provides the results of a prospective study using molecular diagnostics to assess the epidemiology and clinical presentation of RVIs in HSCT recipients.
4. Roghmann M, Ball K, Erdman D, et al. Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripheral blood stem cell transplantation. Bone Marrow Transplant 2003; 32: 1085-1088.
5. Rovida F, Percivalle E, Zavattoni M, et al. Monoclonal antibodies versus reverse transcription-PCR for detection of respiratory viruses in a patient population with respiratory tract infections admitted to hospital. J Med Virol 2005; 75:336-347.
6. Kim YJ, Boeckh M, Englund JA. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin Respir Crit Care Med 2007; 28:222-242.
7. Nichols WG, Gooley T, Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant 2001; 7 (Suppl):11S-15S.
8. Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004; 39:1300-1306.
9. Zambon MC, Stockton JD, Clewley JP, Fleming DM. Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet 2001; 358:1410-1416.
10. Chakrabarti S, Collingham KE, Marshall T, et al. Respiratory virus infections in adult T cell-depleted transplant recipients: the role of cellular immunity. Transplantation 2001; 72:1460-1463.
11. Ljungman P, Ward KN, Crooks BN, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2001; 28:479-484.
12. Chien JW, Martin PJ, Gooley TA, et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003; 168:208-214.
13. Erard V, Chien JW, Kim HW, et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J Infect Dis 2006; 193:1619-1625.
14. Anderson EJ. Viral diagnostics and antiviral therapy in hematopoietic stem cell transplantation. Curr Pharm Des 2008; 14:1997-2010.
15. Englund JA, Piedra PA, Jewell A, et al. Rapid diagnosis of respiratory syncytial virus infections in immunocompromised adults. J Clin Microbiol 1996; 34:1649-1653.
16. Landry ML, Ferguson D. SimulFluor respiratory screen for rapid detection of multiple respiratory viruses in clinical specimens by immunofluorescence staining. J Clin Microbiol 2000; 38:708-711.
17. Landry ML, Ferguson D, Cohen S, et al. Detection of human metapneumovirus in clinical samples by immunofluorescence staining of shell vial centrifugation cultures prepared from three different cell lines. J Clin Microbiol 2005; 43:1950-1952.
18. Lotlikar M, Manji R, Falk L, et al. Detection of hMPV in respiratory specimens using DHI's D3 Ultra 8 DFA respiratory virus detection kit, DHl's MPV specific DFA reagent, R-mix cultures, and Nuclisens ASRS. In: Clinical Virology Symposium; Clearwater, Florida, USA; 2007.
19. Fox JD. Nucleic acid amplification tests for detection of respiratory viruses. J Clin Virol 2007; 40 (Suppl 1):S15-S23. A clear review of the benefit of molecular diagnosis over alternative diagnostic methods for detecting respiratory viruses.
20. Asian T, Passas AB, Desikan R, et al. Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapy. Bone Marrow Transplant 1999; 24: 505-509.
21. Wu H, Pfarr DS, Losonsky GA, Kiener PA. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol 2008; 317:103-123.
22. Nichols WG, Peck Campbell AJ, Boeckh M. Respiratory viruses other than influenza virus: impact and therapeutic advances. Clin Microbiol Rev 2008; 21:274-290. A review of all agents that have undergone and are currently undergoing clinical investigation for the treatment of RVIs.
23. Boeckh M, Englund J, Li Y, et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis 2007; 44:245-249. Report of a prospective study of aerosolized ribavirin that suggested that the therapy was well tolerated and resulted in a trend of decreasing viral load over time.
24. Chemaly RF, Ghosh S, Bodey GP, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 2006; 85:278-287.
25. Chakrabarti S, Collingham KE, Holder K, et al. Preemptive oral ribavirin therapy of paramyxovirus infections after haematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplant 2001; 28:759-763.
26. Chavez-Bueno S, Mejias A, Merryman RA, et al. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatrie patients. Pediatr Infect Dis J 2007; 26:1089-1093.
27. Chapman J, Abbott E, Alber DG, et al. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother 2007; 51:3346-3353.
28. Marty F, Chemaly RF, Liaopoulou E, et al. A double-blind, randomised, placebo-controlled study to evaluate the safety and efficacy of RSV604 in adults with respiratory syncytial virus (RSV) infection following stem cell transplantation. In: IX International Symposium on Respiratory Viral Infections; Hong Kong; 2007.
29. DeVincenzo J, Cehelsky JE, Alvarez R, et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res 2008; 77:225-231.
30. Mejias A, Chavez-Bueno S, Raynor MB, et al. Motavizumab, a neutralizing anti-Respiratory Syncytial Virus (Rsv) monoclonal antibody significantly modifies the local and systemic cytokine responses induced by Rsv in the mouse model. Virol J 2007; 4:109.
31. Oliveira RR, Machado AF, Tateno AF, et al. Frequency of human metapneumovirus infection in hematopoietic SCT recipients during 3 consecutive years. Bone Marrow Transplant 2008; 42:265-269. A large retrospective study of hMPV in HSCT recipients that provides insight into the epidemiology and clinical course of hMPV in this population.
32. Cane PA, van den Hoogen BG, Chakrabarti S, et al. Human metapneumovirus in a haematopoietic stem cell transplant recipient with fatal lower respiratory tract disease. Bone Marrow Transplant 2003; 31:309-310.
33. Debiaggi M, Canducci F, Sampaolo M, et al. Persistent symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients. J Infect Dis 2006; 194:474-478.
34. Debiaggi M, Canducci F, Terulla C, et al. Long-term study on symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients. New Microbiol 2007; 30:255-258.
35. Englund JA, Boeckh M, Kuypers J, et al. Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med 2006; 144:344-349.
36. Huck B, Egger M, Bertz H, et al. Human metapneumovirus infection in a hematopoietic stem cell transplant recipient with relapsed multiple myeloma and rapidly progressing lung cancer. J Clin Microbiol 2006; 44:2300-2303.
37. Muller A, Kupfer B, Vehreschild J, et al. Fatal pneumonia associated with human metapneumovirus (HMPV) in a patient with myeloid leukemia and adenocarcinoma in the lung. Eur J Med Res 2007; 12:183-184.
38. Raza K, Ismailjee SB, Crespo M, et al. Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J Heart Lung Transplant 2007; 26:862-864. The only published report of treatment of hMPV with ribavirin in a transplant recipient in the literature currently.
39. Hamelin ME, Prince GA, Boivin G. Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection. Antimicrob Agents Chemother 2006; 50:774-777.
40. Wyde PR, Chetty SN, Jewell AM, et al. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res 2003; 60:51-59.
41. Chakrabarti S, Avivi I, Mackinnon S, et al. Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality. Br J Haematol 2002; 119:1125-1132.
42. Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57:1-60. Current US recommendations on prevention and treatment of influenza for the 2008-2009 influenza season; it includes specific recommendations about vaccination of transplant recipients and their caretakers.
43. Machado CM, Boas LS, Mendes AV, et al. Use of Oseltamivir to control influenza complications after bone marrow transplantation. Bone Marrow Transplant 2004; 34:111-114.
44. Bright RA, Shay DK, Shu B, et al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006; 295:891-894.
45. Vu D, Peck AJ, Nichols WG, et al. Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study. Clin Infect Dis 2007; 45:187-193. A retrospective case-control study of oseltamivir in the prevention of influenza, which documented significant protective efficacy of this intervention.
46. Ison MG, Sharma A, Shepard JA, et al. Outcome of influenza infection managed with oseltamivir in lung transplant recipients. J Heart Lung Transplant 2008; 27:282-288.
47. Kobayashi S, Kimura F, Kobayashi A, et al. Influenza virus reactivation after remission with oseltamivir treatment in a patient undergoing nonmyeloablative bone marrow transplantation. J Infect Chemother 2008; 14:308-310.
48. Medeiros R, Rameix-Welti MA, Lorin V, et al. Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus. Antivir Ther 2007; 12:571-576.
49. Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther 2007; 12:603-616.
50. Baz M, Abed Y, McDonald J, Boivin G. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 2006; 43:1555-1561.
51. Ison MG, Gubareva LV, Atmar RL, et al. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 2006; 193:760-764.
52. Gubareva LV. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res 2004; 103:199-203.
53. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group [see comments]. JAMA 2000; 283:1016-1024.
54. Ison MG, Gnann JW Jr, Nagy-Agren S, et al. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 2003; 8:183-190.
55. Furuta Y, Takahashi K, Kuno-Maekawa M, et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 2005; 49: 981-986.
56. Takahashi K, Furuta Y, Fukuda Y, et al. In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antivir Chem Chemother 2003; 14:235-241.
57. Malakhov MP, Aschenbrenner LM, Smee DF, et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006; 50:1470-1479.
58. Ong AK, Hayden FG. John F. Enders Lecture 2006: antivirals for influenza. J Infect Dis 2007; 196:181-190. A review of emerging therapies for influenza.
59. Ison MG. Adenovirus infections in transplant recipients. Clin Infect Dis 2006; 43:331-339.
60. Erard V, Huang ML, Ferrenberg J, et al. Quantitative real-time polymerase chain reaction for detection of adenovirus after T cell-replete hematopoietic cell transplantation: viral load as a marker for invasive disease. Clin Infect Dis 2007; 45:958-965. A retrospective study of the epidemiology of adenovirus DNA-emia in an adult HSCT population. The study found that adenovirus DNA-emia was a rare finding but when sustained or high-level viremia was noted, it was a specific and sensitive indicator of disease.
61. Chakrabarti S. Adenovirus infections after hematopoietic stem cell transplantation: still unravelling the story. Clin Infect Dis 2007; 45:966-968.
62. Anderson EJ, Guzman-Cottrill JA, Kletzel M, et al. High-riskadenovirus-infected pediatric allogeneic hematopoietic progenitor cell transplant recipients and preemptive cidofovir therapy. Pediatr Transplant 2008; 12:219-227.
63. Ghosh S, Champlin R, Couch R, et al. Rhinovirus infections in myelosup-pressed adult blood and marrow transplant recipients. Clin Infect Dis 1999; 29:528-532.
64. Gutman JA, Peck AJ, Kuypers J, Boeckh M. Rhinovirus as a cause of fatal lower respiratory tract infection in adult stem cell transplantation patients: a report of two cases. Bone Marrow Transplant 2007; 40:809-811.
65. Ison MG, Hayden FG, Kaiser L, et al. Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia. Clin Infect Dis 2003; 36:1139-1143.
66. Kupfer B, Vehreschild J, Comely O, et al. Severe pneumonia and human bocavirus in adult. Emerg Infect Dis 2006; 12:1614-1616.
67. Schenk T, Strahm B, Kontny U, et al. Disseminated bocavirus infection after stem cell transplant. Emerg Infect Dis 2007; 13:1425-1427.
68. Allander T, Tammi MT, Eriksson M, et al. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci U S A 2005; 102:12891-12896.
69. Allander T, Andreasson K, Gupta S, et al. Identification of a third human polyomavirus. J Virol 2007; 81:4130-4136.
70. Gaynor AM, Nissen MD, Whiley DM, et al. Identification of a novel polyomavirus from patients with acute respiratory tract infections. PLoS Pathog 2007; 3:e64.
71. Ferguson P, Gilroy N, Bradstock K, et al. WU and KI polyomaviruses - new respiratory viruses in adult HSCT recipients [abstract 375]. XXII International Congress of the Transplantation Society; Sydney, Australia; 2008.
72. Kuypers J, Peck Campbell AJ, Wright NL, et al. Detection of WDV and KIV polyomaviruses in nasal wash (NW) specimens from hematopoietic cell transplant (HCT) recipients [abstract V-1642]. IDSA/ICAAC; Washington, DC; 2008.